Literature DB >> 18636309

What is new in the management of Helicobacter pylori?

B J Egan1, H J O'Connor, C A O'Morain.   

Abstract

Since the discovery of Helicobacter pylori in the early 1980s several treatment regimens have been developed to effectively treat this infection. International guidelines have allowed consensus on the best management and improved eradication rates. In recent years increasing antimicrobial resistance and falling eradication rates highlight the need for updated guidelines. In this article we review the most recent European management guidelines and in view of the unavailability of some drugs consider new treatment regimens for the management of H. pylori in Ireland.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636309     DOI: 10.1007/s11845-008-0173-8

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  24 in total

1.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice.

Authors:  J M Lee; E Deasy; C A O'Morain
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-04       Impact factor: 2.566

4.  Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.

Authors:  J P Gisbert; J-L Gisbert; S Marcos; I Jimenez-Alonso; R Moreno-Otero; J M Pajares
Journal:  Aliment Pharmacol Ther       Date:  2007-11-12       Impact factor: 8.171

5.  How can the current strategies for Helicobacter pylori eradication therapy be improved?

Authors:  Alex Ford; Paul Moayyedi
Journal:  Can J Gastroenterol       Date:  2003-06       Impact factor: 3.522

6.  One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.

Authors:  Stephan Miehlke; Wulf Schneider-Brachert; Christian Kirsch; Andrea Morgner; Ahmed Madisch; Eberhard Kuhlisch; Christian Haferland; Elke Bästlein; Claus Jebens; Christian Zekorn; Holger Knoth; Manfred Stolte; Norbert Lehn
Journal:  Helicobacter       Date:  2008-02       Impact factor: 5.753

Review 7.  Treatment of Helicobacter pylori.

Authors:  B J Egan; M Katicic; H J O'Connor; C A O'Morain
Journal:  Helicobacter       Date:  2007-10       Impact factor: 5.753

8.  The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice.

Authors:  D Van der Poorten; P H Katelaris
Journal:  Aliment Pharmacol Ther       Date:  2007-09-28       Impact factor: 8.171

9.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

Review 10.  Treatment of Helicobacter pylori and prevention of gastric cancer.

Authors:  Ting Kin Cheung; Benjamin C Y Wong
Journal:  J Dig Dis       Date:  2008-02       Impact factor: 2.325

View more
  4 in total

1.  The phenyl-thiophenyl propenone RK-I-123 reduces the levels of reactive oxygen species and suppresses the activation of NF-κB and AP-1 and IL-8 expression in Helicobacter pylori-infected gastric epithelial AGS cells.

Authors:  Sung Hee Jang; Soonok Cho; Eung-Seok Lee; Jung Mogg Kim; Hyeyoung Kim
Journal:  Inflamm Res       Date:  2013-04-23       Impact factor: 4.575

2.  New Approach in Ulcer Prevention and Wound Healing Treatment using Doxycycline and Amoxicillin/LDH Nanocomposites.

Authors:  Fatma I Abo El-Ela; Ahmed A Farghali; Rehab K Mahmoud; Nada A Mohamed; S A Abdel Moaty
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

3.  Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Authors:  Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki
Journal:  BMC Microbiol       Date:  2009-09-03       Impact factor: 3.605

4.  Helicobacter pylori infection and its association with anemia among adult dyspeptic patients attending Butajira Hospital, Ethiopia.

Authors:  Dargaze Kibru; Baye Gelaw; Agersew Alemu; Zelalem Addis
Journal:  BMC Infect Dis       Date:  2014-12-09       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.